BridgeBio Oncology Therapeutics Inc BBOT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $8.90
- Day Range
- $8.65–9.06
- 52-Week Range
- $7.00–14.87
- Bid/Ask
- $8.93 / $9.03
- Shares Outstanding
- 80.17M
- Market Cap
- $719.96M
- Volume/Avg
- 117,621 / 369,415
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 88
- Website
- https://www.bridgebio.com
Valuation
|
Metric
|
BBOT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.23 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BBOT
Financial Strength
|
Metric
|
BBOT
|
|---|---|
Quick Ratio | 4.38 |
Current Ratio | 4.69 |
Interest Coverage | — |
Quick Ratio
BBOT
Profitability
|
Metric
|
BBOT
|
|---|---|
Return on Assets (Normalized) | −44.35% |
Return on Equity (Normalized) | −62.86% |
Return on Invested Capital (Normalized) | −67.96% |
Return on Assets
BBOT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&WS#c< | LOCK|@&qY | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^pQQ@@? | LOCK|&Qq@W | $85B | |||
| argenx SE ADR
ARGX
| LOCK|h^%CPc | LOCK|Km | $65B | |||
| Moderna Inc
MRNA
| LOCK|yPmr>b | LOCK|vF! | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|tKZqn<Y | LOCK|X^N | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|H^@sP# | LOCK|@@>> | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&JWWsgk@ | LOCK|j?lj | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|?%mdtJx | LOCK|Kq# | $26B | |||
| Incyte Corp
INCY
| LOCK|PZ!NL&% | LOCK|<^K | $26B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|sXRmbN | LOCK|pL | $16B |
United States